glp-1 retatrutide vs Semaglutide and Tirzepatide: GLP-3 Facts explained New GLP-1 obesity drug, retatrutide,

Key Takeaways TRIUMPH-4 (obesity + knee osteoarthritis) reported 28.7% mean weight loss at 12 mg / 68 weeks TRANSCEND-T2D-1 reported HbA1c reductions up to 2.0%, read out March 19, 2026 A new safety signal dysesthesia (abnormal skin sensations) was observed at 20.9% incidence at the 12 mg dose NDA filing is expected Q4 2026

Russell-Jones D, Vaag A, Schmitz O, et al

Keep in mind that consistent use, along with a healthy diet and exercise, leads to the best outcomes

Feb 28, 2026 What if the injection site you have been using is quietly undermining your weight loss results

Julia Edelman Executive Director of Womens Health Julia Schlam Edelman, MD is a gynecologist, author, and public speaker

DEXA scan at 24 weeks compared to baseline quantifies the body composition changes